Decision: Favourable

Decisions Table

Study Title:

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VR

  • NREC Code:

    22-NREC-CT-102

  • Decision:

    Favourable

  • Meeting Date:

    08/06/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Christopher Bacon

  • PI Institution:

    St James' Hospital

  • Sponsor:

    Janssen-Cilag International NV

Scroll to Top